Welcome to our dedicated page for ZEO ScientifiX SEC filings (Ticker: zeox), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZEO ScientifiX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZEO ScientifiX's regulatory disclosures and financial reporting.
ZEO ScientifiX, Inc. filed a report describing a business milestone rather than financial results. The company announced that its monthly Masterclass series in regenerative biologics has now trained over 500 clinicians, with each one-day session typically hosting more than 70 attendees at Nova Southeastern University in Florida.
The curriculum focuses on Florida regulatory requirements, evidence-based science, and operational frameworks for responsibly integrating regenerative biologics such as stem cells and extracellular vesicles into medical practice. The next Masterclass is scheduled for April 24 and is limited to clinicians and practice owners.
ZEO ScientifiX, Inc. reported that it has entered into a memorandum of understanding with Regen Therapy for an exclusive scientific and biologics strategic collaboration. ZEO is positioned as the core supplier of advanced biologic therapeutics for Regen’s next-generation regenerative offerings across a network of more than 3,000 clinics and 24,000 practitioners in the U.S. The collaboration is paired with Regen Therapy’s partnership with Stealth Health and integration of the Metabolic Code precision health platform to create a vertically integrated ecosystem for telemedicine-driven longevity and regenerative care.
ZEO ScientifiX, Inc. reported that it has been selected as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan competition. This is a $101 million global contest aimed at therapeutics that restore muscle, cognitive, and immune function by at least 10 years in older adults.
The company is now preparing its Finals Application and plans to move its regenerative biologics platform into controlled clinical evaluation during the Semi-Finals. ZEO focuses on extracellular vesicle (exosome) therapeutics and advanced delivery systems targeting biological mechanisms of aging and inflammation, operating from laboratories at Nova Southeastern University.
ZEO ScientifiX, Inc. filed an 8-K to highlight a new educational partnership with the American Academy of Anti-Aging Medicine (A4M) for Longevity SpringFest 2026. ZEO will serve as A4M’s official regenerative medicine education partner and lead a full-day Masterclass on April 9, 2026, in West Palm Beach, Florida.
The collaboration provides ZEO direct access to A4M’s network of 26,000 physicians and health care practitioners across more than 120 countries, positioning the company within the broader $29.9 billion longevity therapy market. ZEO describes itself as a clinical-stage biopharmaceutical company focused on regenerative biologics, operating from Nova Southeastern University’s $100 Million Center of Collaborative Research.
Zeo ScientifiX, Inc. reported that, effective March 23, 2026, it terminated the employment of Dr. John D. Kisiday, Ph.D. as its Chief Science Officer. This change removes a key scientific executive from the leadership team, and the company has not described any replacement or transition details in this excerpt.
Zeo ScientifiX, Inc. reported strong top-line growth but continued losses and liquidity pressure for the quarter ended January 31, 2026. Revenue rose to $1.446M from $1.09M, a 32.7% increase driven by higher sales of allogenic aesthetic biologics and its PPX™ service platform. Gross profit improved to $1.165M, or 80.6% of revenue, while the net loss narrowed to $852,000 from $1.243M, or $0.12 per share. Operating cash flow was negative $471,000, and Zeo ended the quarter with $1.03M in cash, total assets of $2.571M, liabilities of $2.954M, and a stockholders’ deficit of $383,000. The company funded operations through $1.3M of private unit sales during the quarter and an additional $650,000 raised in February 2026. Management highlights growth opportunities from Florida’s new stem cell law (SB 1768) and an IRB-approved PPX™ musculoskeletal study, but reiterates substantial doubt about Zeo’s ability to continue as a going concern due to accumulated deficits, a working capital deficit of $879,000, dependence on external capital, and regulatory uncertainty around FDA biologics enforcement.
Zeo Scientifix, Inc. investor Wendy Grey, through Greyt Ventures, LLC, filed Amendment No. 1 to a Schedule 13D updating her ownership and voting power. She now beneficially owns 1,405,000 shares of common stock, including 1,155,000 shares issuable upon exercise of warrants.
Based on 7,614,941 common shares outstanding as of January 28, 2026, this represents 17.52% of the common stock voting power. Grey also holds 50 shares of Series C Preferred Stock that provide an additional 25.5% of total voting power, giving her aggregate voting power of 43.02%. The added position reflects warrant grants under Zeo Scientifix’s 2021 Equity Incentive Plan in July 2024 and May 2025, and she currently has sole voting and dispositive power over all reported shares while stating no definite plans for major corporate changes.
Zeo ScientifiX, Inc. reported the initial holdings of its Chief Science Officer, David John Kisiday, in a Form 3. He beneficially owns 50,000 shares of common stock, all in the form of restricted stock granted on January 23, 2026 under the company’s 2021 Equity Incentive Plan.
The grant vests over two years, with 20,000 shares vesting on the first anniversary of Mr. Kisiday’s employment agreement effective January 23, 2026 and 30,000 shares vesting on the second anniversary. Vesting is contingent on his continued service and the other terms of the incentive plan.
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company focused on regenerative medicine and degenerative disease therapies. Its lead products, including Zofin™ and Patient Pure X™ (PPX™), use birth-tissue and blood-derived nanoparticles manufactured in FDA-registered, cGMP-compliant labs.
The company is repositioning around Florida’s new stem cell law SB 1768, which permits certain non-FDA-approved stem cell treatments for orthopedic, wound care, and pain indications. Zeo plans to leverage this framework to grow revenue, collect real‑world data, and advance clinical programs at lower cost.
Zeo reported a net loss of $5,521,000 for the year ended October 31, 2025, with an accumulated deficit of $67,734,000 and a working capital deficit of $1,915,000. Auditors raised substantial doubt about its ability to continue as a going concern. The company is pursuing partnerships, acquisitions, international sales, and a broad patent and trademark portfolio to support future growth amid significant FDA and funding risks.
Zeo ScientifiX, Inc. appointed Dr. John D. Kisiday as Chief Science Officer effective January 23, 2026. He brings nearly 30 years of experience in tissue engineering and regenerative medicine, including work with cell-based, biomaterial and drug-based orthopedic therapies and extensive academic research leadership.
Under an employment agreement effective the same date, Dr. Kisiday receives a $175,000 base salary and a 50,000-share stock grant under the 2021 Incentive Plan, vesting 20,000 shares after one year and 30,000 shares after two years, contingent on continued employment. His role is at-will and includes a tenure-based severance formula for termination without cause or for good reason, plus customary confidentiality, non-compete and non-solicitation covenants.